GSK cuts prices on 'essential' Kenyan meds by 50%


Following through on a pledge to reduce the cost of its meds in the developing world, GlaxoSmithKline is rolling out price cuts in Kenya. The company's Kenyan unit will reduce prices on "essential" drugs by 50 percent, local Managing Director John Musunga told Bloomberg.

The move is not a purely altruistic one. Improving patient access to medicines can boost the volume of sales, and in emerging markets, higher volumes may make up for the lower prices. Musunga told Capital Business that, after cutting the price of its leading antibiotic by 40 percent, GSK saw a 60 percent increase in volume, thus compensating for the price change.

"What that has shown us is that people like good-quality medicine, but are not able to afford it," Musunga told Bloomberg. "We cannot afford to focus only on the high-income social groups."

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download today and learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

The Kenyan changes are part of a companywide effort to cut the prices of its drugs in the developing world, in some cases to as low as one-fourth their cost in developed markets, GSK said in a statement. This latest round of price decreases in Kenya follows cuts to the cost of 13 drugs there since 2009.

- read the Bloomberg news

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.